Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

Second-line treatment of small-cell lung cancer (SCLC) may include chemotherapy, immunotherapy, and palliative care. While some people respond to second-line treatments, the outlook for people with ...

Panelists discuss how NCCN guidelines are expected to incorporate quadruplet-based regimens as reasonable treatment approaches for transplant-ineligible patients, while emphasizing the need for ...

Please provide your email address to receive an email when new articles are posted on . Survival outcomes with the sacituzumab govitecan combination outweighed outcomes with chemotherapy combination ...

The selection of a first-line treatment for patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) has become increasingly complex in recent years with available options now including ...